3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
40
Neoplasms
8
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Quality of Life
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Hot Flashes
1
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Gynecomastia
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Subjects
1
Breast Cancer Metastatic
1
Breast Cancer Female
1
Bone Density
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Interventions
Trastuzumab
3
Docetaxel
3
Gemcitabine
2
tusamitamab ravtansine
1
nirogacestat
1
margetuximab
1
exemestane
1
Vinorelbine
1
Tamoxifen
1
Letrozole
1
Fulvestrant
1
Capecitabine
1
Anastrozole
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Cancer Metastatic
×
Tamoxifen
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts